The incorporation of immune checkpoint-based therapies targeting the programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) axis earlier into the treatment paradigm of advanced NSCLC has resulted in considerable long-term survival benefit for patients. Here, CD274 is linked to non-small cell lung carcinoma.